Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ben-Horin

Showing results (271-280 of 362) with videos related to

Pageof 37
Sort By:
BMJ Open|February 21, 2019
Efficacy of biological drugs in short-duration versus long-duration inflammatory bowel disease: a protocol for a systematic review and an individual-patient level meta-analysis of randomised controlled trialsShomron Ben-Horin, Yue Zhao, Jing Guo, et al.
Alimentary Pharmacology & Therapeutics|December 2, 2010
The efficacy of shortening the dosing interval to once every six weeks in Crohn's patients losing response to maintenance dose of infliximabU Kopylov, G J Mantzaris, K H Katsanos, et al.
United European Gastroenterology Journal|October 20, 2020
Infliximab clearance decreases in the second and third trimesters of pregnancy in inflammatory bowel diseaseAna-Marija Grišić, Maria Dorn-Rasmussen, Bella Ungar, et al.
Medicine|May 8, 2015
Ashkenazi Jewish origin protects against formation of antibodies to infliximab and therapy failureBella Ungar, Ola Haj-Natour, Uri Kopylov, et al.
Inflammatory Bowel Diseases|January 13, 2015
Inflammatory bowel disease: an emergent disease among Ethiopian Jews migrating to IsraelAriella Bar-Gil Shitrit, Benjamin Koslowsky, Michal Kori, et al.
Gastroenterology|May 27, 2014
Effects of vedolizumab induction therapy for patients with Crohn's disease in whom tumor necrosis factor antagonist treatment failedBruce E Sands, Brian G Feagan, Paul Rutgeerts, et al.
Journal of Crohn'S & Colitis|September 1, 2018
Pharmacokinetics and Immune Reconstitution Following Discontinuation of Thiopurine Analogues: Implications for Drug Withdrawal StrategiesShomron Ben-Horin, Gert Van Assche, Yehuda Chowers, et al.
Gastroenterology|November 10, 2021
Efficacy of Biologic Drugs in Short-Duration Versus Long-Duration Inflammatory Bowel Disease: A Systematic Review and an Individual-Patient Data Meta-Analysis of Randomized Controlled TrialsShomron Ben-Horin, Lena Novack, Ren Mao, et al.
Alimentary Pharmacology & Therapeutics|April 20, 2016
Induction infliximab levels among patients with acute severe ulcerative colitis compared with patients with moderately severe ulcerative colitisB Ungar, Y Mazor, R Weisshof, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|December 11, 2017
Association of Vedolizumab Level, Anti-Drug Antibodies, and α4β7 Occupancy With Response in Patients With Inflammatory Bowel DiseasesBella Ungar, Uri Kopylov, Miri Yavzori, et al.
Pageof 37

Showing results (271-280 of 362) with videos related to

Sort By:
Pageof 37
BMJ Open|February 21, 2019
Efficacy of biological drugs in short-duration versus long-duration inflammatory bowel disease: a protocol for a systematic review and an individual-patient level meta-analysis of randomised controlled trialsShomron Ben-Horin, Yue Zhao, Jing Guo, et al.
Alimentary Pharmacology & Therapeutics|December 2, 2010
The efficacy of shortening the dosing interval to once every six weeks in Crohn's patients losing response to maintenance dose of infliximabU Kopylov, G J Mantzaris, K H Katsanos, et al.
United European Gastroenterology Journal|October 20, 2020
Infliximab clearance decreases in the second and third trimesters of pregnancy in inflammatory bowel diseaseAna-Marija Grišić, Maria Dorn-Rasmussen, Bella Ungar, et al.
Medicine|May 8, 2015
Ashkenazi Jewish origin protects against formation of antibodies to infliximab and therapy failureBella Ungar, Ola Haj-Natour, Uri Kopylov, et al.
Inflammatory Bowel Diseases|January 13, 2015
Inflammatory bowel disease: an emergent disease among Ethiopian Jews migrating to IsraelAriella Bar-Gil Shitrit, Benjamin Koslowsky, Michal Kori, et al.
Gastroenterology|May 27, 2014
Effects of vedolizumab induction therapy for patients with Crohn's disease in whom tumor necrosis factor antagonist treatment failedBruce E Sands, Brian G Feagan, Paul Rutgeerts, et al.
Journal of Crohn'S & Colitis|September 1, 2018
Pharmacokinetics and Immune Reconstitution Following Discontinuation of Thiopurine Analogues: Implications for Drug Withdrawal StrategiesShomron Ben-Horin, Gert Van Assche, Yehuda Chowers, et al.
Gastroenterology|November 10, 2021
Efficacy of Biologic Drugs in Short-Duration Versus Long-Duration Inflammatory Bowel Disease: A Systematic Review and an Individual-Patient Data Meta-Analysis of Randomized Controlled TrialsShomron Ben-Horin, Lena Novack, Ren Mao, et al.
Alimentary Pharmacology & Therapeutics|April 20, 2016
Induction infliximab levels among patients with acute severe ulcerative colitis compared with patients with moderately severe ulcerative colitisB Ungar, Y Mazor, R Weisshof, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|December 11, 2017
Association of Vedolizumab Level, Anti-Drug Antibodies, and α4β7 Occupancy With Response in Patients With Inflammatory Bowel DiseasesBella Ungar, Uri Kopylov, Miri Yavzori, et al.
Pageof 37